What makes cetirizine a unique anti-inflammatory option for your scalp?

The scalp, like other areas of the skin, can become inflamed for many reasons: allergies, seborrheic dermatitis, infections, buildup of cosmetic products, or in response to hormonal changes or stress. When this inflammation is not controlled, it can disrupt the natural hair cycle and lead to hair loss or progressive weakening. Among the topical and oral treatments used to manage these symptoms, cetirizine—commonly known as an oral antihistamine for allergies—has begun to draw attention as a possible topical option for scalp inflammation. What is it about this molecule, originally developed for allergic rhinitis, that researchers find interesting?

From allergy relief to scalp soother: the unexpected shift of cetirizine

Cetirizine is a second-generation antihistamine that works by blocking the action of histamine, a natural substance the body releases during an allergic reaction. By blocking H1 receptors (the specific type that triggers symptoms like itching, redness, or discharge), cetirizine prevents the associated inflammatory cascade. It has been used for decades in oral tablet form to treat nasal and skin allergies. A small number of recent studies have explored applying it directly to the scalp, but there is no approved topical cetirizine product: the scalp solutions used in those studies were compounded for research, so any topical use is off-label and unregulated.

What researchers say sets cetirizine apart from other topical anti-inflammatory agents is its reported ability to modulate not only histamine but also other inflammatory mediators. In laboratory work, cetirizine has been reported to reduce pro-inflammatory prostaglandins such as PGD2, a substance that participates in inflammatory processes and has also been linked to inhibiting hair growth.

Why is PGD2 key in inflammation-related hair loss?

PGD2, or prostaglandin D2, is a lipid that is naturally produced in the body and serves immunological functions. In 2012, a study led by Garza et al. at the University of Pennsylvania found that men with androgenetic alopecia (the most common form of hair loss) had higher levels of PGD2 in bald scalp than in haired scalp. The authors reported that PGD2 inhibits hair growth in laboratory models, which is why it has been proposed as a target for treatment.

Laboratory work reports that cetirizine lowers PGD2; this is the mechanism cited when it is proposed for the scalp. No published study has measured PGD2 in the scalp before and after applying topical cetirizine, so the step from the mechanism to a clinical effect has not been demonstrated.

Beyond itching: clinical effects observed in real patients

The most cited clinical study is a 2018 pilot by Rossi et al. at Sapienza University of Rome, published in the Journal of Dermatological Treatment. It recruited 85 patients with androgenetic alopecia, of whom 67 were treated with 1% topical cetirizine and 18 acted as controls. Results were measured by trichoscopy — hair density counts and hair diameter — before and after treatment.

What the authors reported: an increase in total hair density, terminal hair density and hair diameter, a fall in vellus (fine) hair density, and no notable side effects during the study. The published summary describes the controls as a placebo comparison but does not report randomization or blinding, and the study was small. It did not measure scalp inflammation as an outcome. The authors describe it as a preliminary study; it is a reason for further research rather than proof that cetirizine treats scalp inflammation.

Two small randomized trials have also been published, both in pattern hair loss. In 40 men, 1% cetirizine was compared with 5% minoxidil for 16 weeks, and improvement was larger with minoxidil (Hossein Mostafa et al., 2021). In 66 women, cetirizine plus minoxidil was compared with placebo plus minoxidil for 24 weeks, and the authors reported greater hair shaft thickness with cetirizine added (Bassiouny et al., 2023). Neither trial measured scalp inflammation.

How safe is topical cetirizine for the scalp?

Topical corticosteroids, another class of commonly used scalp anti-inflammatory agents, carry known risks with prolonged use such as skin thinning. Cetirizine works by a different mechanism and is not a steroid, so it does not carry that particular risk. That is not the same as being safe for long-term use: no study has followed people using topical cetirizine on the scalp for longer than about six months, so the long-term effects are simply unknown.

The Food and Drug Administration has not approved topical cetirizine for scalp use, or for any use — cetirizine's approvals cover oral formulations, whose side effects (drowsiness in some people, dry mouth, and less commonly others listed on the label) are well characterised from decades of allergy use. How much cetirizine is absorbed through the scalp from a compounded solution has not been well studied, and will depend on the carrier the pharmacy used.

Does it work for all types of scalp inflammation?

There is no clinical evidence for cetirizine in scalp conditions other than androgenetic alopecia, so what follows is reasoning about mechanism, not tested treatment. In seborrheic dermatitis, where yeasts like Malassezia are involved, an anti-inflammatory effect would not address the cause without a concurrent antifungal treatment. In conditions driven by immune or irritative responses—such as allergic contact dermatitis, or androgenetic alopecia with an inflammatory component—an antihistamine is at least mechanistically plausible. Telogen effluvium is a different case: it is generally a shedding response to stress, illness, childbirth or nutritional deficiency rather than an inflammatory disease, and there is no reason to expect cetirizine to treat it. Persistent scalp inflammation, itching or scaling should be diagnosed by a clinician, because the treatment depends entirely on the cause.

Conclusion: What makes cetirizine unique for inflamed scalp conditions?

The interest in cetirizine comes from its reported action on several inflammatory mediators, especially PGD2, which is not how the standard scalp anti-inflammatories work. Unlike corticosteroids, it does not carry a skin-thinning risk. But the clinical evidence is a few small trials in pattern hair loss (none in inflammatory scalp disease), and there is no approved product, no standard concentration and no established protocol. On the current evidence, topical cetirizine is an experimental, off-label idea worth studying, not an established treatment for an inflamed scalp.

Talk to a doctor or pharmacist before starting, stopping or combining topical cetirizine — particularly if you are already using a prescription scalp treatment, or if the inflammation has not been diagnosed.

References

Garza, L. A., Liu, Y., Yang, Z., Alagesan, B., Lawson, J. A., Norberg, S. M., ... & Cotsarelis, G. (2012). Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Science Translational Medicine, 4(126), 126ra34. https://pubmed.ncbi.nlm.nih.gov/22440736/

Rossi, A., Campo, D., Fortuna, M. C., Garelli, V., Pranteda, G., De Vita, G., Sorriso-Valvo, L., Di Nunno, D., & Carlesimo, M. (2018). A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. Journal of Dermatological Treatment, 29(2), 149-151. https://pubmed.ncbi.nlm.nih.gov/28604133/

Hossein Mostafa, D., Samadi, A., Niknam, S., Nasrollahi, S. A., Guishard, A., & Firooz, A. (2021). Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study. Journal of Pharmacy & Pharmaceutical Sciences, 24, 191-199. https://pubmed.ncbi.nlm.nih.gov/33909554/

Bassiouny, E. A., El-Samanoudy, S. I., Abbassi, M. M., Nada, H. R., & Farid, S. F. (2023). Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study. Archives of Dermatological Research, 315(5), 1293-1304. https://pubmed.ncbi.nlm.nih.gov/36571611/